LXRX (Lexicon Pharmaceuticals Inc) Earnings per share for the last four quarters
Lexicon Pharmaceuticals (LXRX) is developing independently of macroeconomic trends, as business success is tied to regulatory approval of new kidney and heart treatments. This chart of EPS (ttm) quotes with a value of 21.20 confirms that the company's progress is driven by clinical data rather than market cycles. Stable demand for diabetes therapy and patent protection create sustainable consumption inertia with high margins.
LXRX (Lexicon Pharmaceuticals): analytical breakdowns and indicator data
Year-over-year (YoY) EPS growth (TTM) measures the dynamics of net income per share by comparing the current twelve-month period with the same period last year. This method neutralizes quarterly volatility, separating sustainable operating profitability from one-off financial factors. By analyzing the current EPS YoY shift over the last 12 months, an investor can discern the actual pace of business scaling. For Lexicon Pharmaceuticals (LXRX), this confirms the commercial effectiveness of their targeted drugs in cardiology and endocrinology.